| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| T Yamaji, M Ishibashi, A Teramoto, T Fukushim. Prolactin secretion by mixed ACTH-prolactin pituitary adenoma cells in culture. Acta endocrinologica. vol 108. issue 4. 1985-06-20. PMID:2859725. |
dopamine and somatostatin, on the other hand, uniformly suppressed prl secretion from acth-prl adenomas as well as from prolactinoma cells. |
1985-06-20 |
2023-08-11 |
Not clear |
| E Ghigo, E Ciccarelli, A Novelli, M Massobrio, E E Müller, F Camann. Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia. Journal of endocrinological investigation. vol 8. issue 1. 1985-06-03. PMID:3989236. |
to better understand the state of dopamine (da) neurotransmission in the tuberoinfundibular da system (tida), monoiodotyrosine (3-iodo-l-tyrosine, mit), a potent inhibitor of da synthesis, was acutely administered to 8 normal women, 7 postpartum women, 8 women with pathological hyperprolactinemia and 5 women after successful removal of a prolactinoma. |
1985-06-03 |
2023-08-11 |
human |
| D Eljarmak, A M Marchisio, M Lis, R Coll. Presence of high affinity dopamine receptors in estrone-induced, prolactin-secreting rat pituitary adenomas: a model for human prolactinomas. Hormone research. vol 21. issue 2. 1985-05-23. PMID:3920132. |
presence of high affinity dopamine receptors in estrone-induced, prolactin-secreting rat pituitary adenomas: a model for human prolactinomas. |
1985-05-23 |
2023-08-11 |
human |
| D Oliva, L Vallar, G Giannattasio, A Spada, S Nicosi. Combined effects of vasoactive intestinal peptide and dopamine on adenylate cyclase in prolactin-secreting cells. Peptides. vol 5. issue 6. 1985-05-15. PMID:6531270. |
vip stimulates adenylate cyclase activity of male and female rat anterior pituitaries and human prolactinomas, while dopamine inhibits the enzyme activity of female rat pituitaries and prolactinomas. |
1985-05-15 |
2023-08-12 |
human |
| D Oliva, L Vallar, G Giannattasio, A Spada, S Nicosi. Combined effects of vasoactive intestinal peptide and dopamine on adenylate cyclase in prolactin-secreting cells. Peptides. vol 5. issue 6. 1985-05-15. PMID:6531270. |
in fact, in female rat pituitaries and in human prolactinomas, the curves for dopamine +/- vip and for vip +/- dopamine were parallel, indicating that the two agents exherted their effects independently from one another. |
1985-05-15 |
2023-08-12 |
human |
| K Y Ho, G A Smythe, L Lazaru. Enhanced hypothalamic dopaminergic inhibition of LH, TSH and GH release in patients with pathological hyperprolactinaemia. Acta endocrinologica. vol 108. issue 3. 1985-05-13. PMID:3984660. |
recent studies have suggested that patients with prolactinomas have a defect in the central regulation of prolactin (prl) release but it is not clear whether the defect results from a true loss of hypothalamic dopamine activity or from a functional inability of inherent dopaminergic inhibition to be mediated effectively. |
1985-05-13 |
2023-08-11 |
human |
| M Ishibashi, T Yamaj. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture. The Journal of clinical endocrinology and metabolism. vol 60. issue 5. 1985-05-10. PMID:2858494. |
in prolactinoma cells, somatostatin and dopamine unequivocally suppressed prl secretion; however, other stimuli including ghrh, vip, and crf were ineffective. |
1985-05-10 |
2023-08-11 |
Not clear |
| D Tallo, W B Malarke. Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas. American journal of obstetrics and gynecology. vol 151. issue 5. 1985-04-23. PMID:3976764. |
physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas. |
1985-04-23 |
2023-08-11 |
human |
| D Tallo, W B Malarke. Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas. American journal of obstetrics and gynecology. vol 151. issue 5. 1985-04-23. PMID:3976764. |
several investigators have suggested that normal responsiveness to dopamine is exhibited by pituitary lactotrophs in patients with idiopathic hyperprolactinemia and prolactinomas. |
1985-04-23 |
2023-08-11 |
human |
| D Tallo, W B Malarke. Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas. American journal of obstetrics and gynecology. vol 151. issue 5. 1985-04-23. PMID:3976764. |
in order to further examine this issue, we infused graded doses of dopamine to normal men and women as well as to patients with idiopathic hyperprolactinemia and prolactinomas. |
1985-04-23 |
2023-08-11 |
human |
| J Dornan, J G O'Leary, N R Fari. Dopamine control of prolactin secretion in multiple endocrine neoplasia type I. Clinical and investigative medicine. Medecine clinique et experimentale. vol 7. issue 3. 1985-03-08. PMID:6151431. |
taking advantage of high prevalence of prolactinomas in newfoundland families with variant multiple endocrine neoplasia type i (men i), we studied the control of prolactin secretion by dopamine in family members with prolactinomas (n = 6), family members who have hyperparathyroidism but no prolactinomas (n = 6), as well as healthy members (n = 8) in unaffected sibships. |
1985-03-08 |
2023-08-12 |
Not clear |
| J Dornan, J G O'Leary, N R Fari. Dopamine control of prolactin secretion in multiple endocrine neoplasia type I. Clinical and investigative medicine. Medecine clinique et experimentale. vol 7. issue 3. 1985-03-08. PMID:6151431. |
dopamine (2 micrograms/kg/min) was less effective in reducing serum prolactin in the prolactinoma group than in the other three groups studied; serum prolactin also showed little rebound in prolactin comparable to controls. |
1985-03-08 |
2023-08-12 |
Not clear |
| S W Lamberts, J G Klÿn, R Oostero. Mechanism of action and tolerance of mesulergine. Clinical pharmacology and therapeutics. vol 36. issue 5. 1984-12-07. PMID:6488683. |
mesulergine did not directly inhibit prl release by cultured normal rat pituitary cells and human prolactinoma cells and it antagonized the action of dopamine in a dose-dependent manner. |
1984-12-07 |
2023-08-12 |
human |
| K J Lee, I Goodrich, M Pensa. Pituitary surgery: current status, including transsphenoidal surgery. American journal of otolaryngology. vol 5. issue 2. 1984-12-05. PMID:6388385. |
bromocriptine, a centrally active dopamine antagonist and ergot derivative, is effective in the treatment of prolactinomas, but it is not effective in the treatment of acromegaly. |
1984-12-05 |
2023-08-12 |
Not clear |
| D G Johnston, K Hall, P Kendall-Taylor, D Patrick, M Watson, D B Coo. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet (London, England). vol 2. issue 8396. 1984-08-30. PMID:6146751. |
effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. |
1984-08-30 |
2023-08-12 |
Not clear |
| D G Johnston, K Hall, P Kendall-Taylor, D Patrick, M Watson, D B Coo. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet (London, England). vol 2. issue 8396. 1984-08-30. PMID:6146751. |
the clinical, radiological, and biochemical effects of dopamine agonist withdrawal after long-term treatment were investigated in seven women and eight men who had been treated for prolactinomas for 1.5 to 7 (mean 3.7) years. |
1984-08-30 |
2023-08-12 |
Not clear |
| D K Sarkar, P E Gottschall, Q W Xie, J Meite. Reduced tuberoinfundibular dopaminergic neuronal function in rats with in situ prolactin-secreting pituitary tumors. Neuroendocrinology. vol 38. issue 6. 1984-08-07. PMID:6738813. |
tuberoinfundibular dopaminergic (tida) neuronal function in rats with spontaneous or estrogen-induced prolactin- (prl-)secreting pituitary tumors (prolactinomas) was studied by assaying dopamine (da) concentration in pituitary stalk blood and electrically induced release of 3h-da from the median eminence in vitro. |
1984-08-07 |
2023-08-12 |
rat |
| D K Sarkar, P E Gottschall, Q W Xie, J Meite. Reduced tuberoinfundibular dopaminergic neuronal function in rats with in situ prolactin-secreting pituitary tumors. Neuroendocrinology. vol 38. issue 6. 1984-08-07. PMID:6738813. |
the dopamine agonist piribedil failed to reduce electrically induced 3h-da release by the superfused median eminence from old rats with prolactinomas, but not from old and young rats without prolactinomas. |
1984-08-07 |
2023-08-12 |
rat |
| A Grossman, B L Cohen, M Charlesworth, P N Plowman, L H Rees, J A Wass, A E Jones, G M Besse. Treatment of prolactinomas with megavoltage radiotherapy. British medical journal (Clinical research ed.). vol 288. issue 6424. 1984-06-05. PMID:6424752. |
the outcome of treatment of 36 women with prolactinomas using megavoltage radiotherapy combined with interim dopamine agonists (bromocriptine, lysuride, pergolide) was reviewed; 16 of the women showed radiological evidence of a macroadenoma. |
1984-06-05 |
2023-08-12 |
Not clear |
| R J Robbins, P A Kern, T L Thompso. Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma. The American journal of medicine. vol 76. issue 5. 1984-06-05. PMID:6720732. |
the use of dopamine antagonists such as thioridazine in patients with prolactinoma may interfere with bromocriptine's action, resulting in potentially serious complications. |
1984-06-05 |
2023-08-12 |
Not clear |